| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2a3dcae58388dc711467989d8e621d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6399ec415053561bfa4acc4ae69b804c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5fa1d887077e960a6e2fb60e142ab58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5bdff8c511c1ebf415aa24177b9d4a62 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56905
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-45 |
| filingDate |
2007-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2010-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d5b1bb47b1e79270d2c1666dbbb60a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f1d83d0b4567905f959b51e19a7cc68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef05502293e2b3dee8dde9b2164f8f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fe1e1a610581adbccd34b9840bf5c69 |
| publicationDate |
2010-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7824908-B2 |
| titleOfInvention |
Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| abstract |
The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies to Toxoplasma gondii . Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination. |
| priorityDate |
2002-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |